vs
Farmland Partners Inc.（FPI）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Farmland Partners Inc.的1.5倍（$30.3M vs $20.7M），Farmland Partners Inc.净利率更高（103.4% vs -221.3%，领先324.8%），REGENXBIO Inc.同比增速更快（43.0% vs -3.5%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 31.4%）
农场土地工业曾是北美规模最大的农业合作社，在2002年至2004年间完成了全部资产出售。在其74年的经营历史中，该合作社作为多元化综合型机构为农户会员提供服务，在北美本土及全球农业市场都发挥过重要作用。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
FPI vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.5倍
$20.7M
营收增速更快
RGNX
高出46.5%
-3.5%
净利率更高
FPI
高出324.8%
-221.3%
两年增速更快
RGNX
近两年复合增速
31.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $20.7M | $30.3M |
| 净利润 | $21.4M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | — | -190.0% |
| 净利率 | 103.4% | -221.3% |
| 营收同比 | -3.5% | 43.0% |
| 净利润同比 | -63.5% | -31.2% |
| 每股收益（稀释后） | $0.44 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FPIRGNX
| Q4 25 | $20.7M | $30.3M | ||
| Q3 25 | $11.3M | $29.7M | ||
| Q2 25 | $10.0M | $21.4M | ||
| Q1 25 | $10.3M | $89.0M | ||
| Q4 24 | $21.5M | $21.2M | ||
| Q3 24 | $13.3M | $24.2M | ||
| Q2 24 | $11.4M | $22.3M | ||
| Q1 24 | $12.0M | $15.6M |
净利润FPIRGNX
| Q4 25 | $21.4M | $-67.1M | ||
| Q3 25 | $483.0K | $-61.9M | ||
| Q2 25 | $7.6M | $-70.9M | ||
| Q1 25 | $2.0M | $6.1M | ||
| Q4 24 | $58.7M | $-51.2M | ||
| Q3 24 | $1.8M | $-59.6M | ||
| Q2 24 | $-2.0M | $-53.0M | ||
| Q1 24 | $1.4M | $-63.3M |
毛利率FPIRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率FPIRGNX
| Q4 25 | — | -190.0% | ||
| Q3 25 | 4.3% | -176.3% | ||
| Q2 25 | 78.2% | -296.3% | ||
| Q1 25 | 20.6% | 13.6% | ||
| Q4 24 | — | -242.1% | ||
| Q3 24 | 13.9% | -256.6% | ||
| Q2 24 | -17.9% | -251.3% | ||
| Q1 24 | 11.9% | -408.8% |
净利率FPIRGNX
| Q4 25 | 103.4% | -221.3% | ||
| Q3 25 | 4.3% | -208.3% | ||
| Q2 25 | 76.3% | -331.8% | ||
| Q1 25 | 19.9% | 6.8% | ||
| Q4 24 | 273.6% | -241.3% | ||
| Q3 24 | 13.5% | -246.3% | ||
| Q2 24 | -17.5% | -237.7% | ||
| Q1 24 | 11.5% | -405.4% |
每股收益（稀释后）FPIRGNX
| Q4 25 | $0.44 | $-1.30 | ||
| Q3 25 | $0.00 | $-1.20 | ||
| Q2 25 | $0.14 | $-1.38 | ||
| Q1 25 | $0.03 | $0.12 | ||
| Q4 24 | $1.09 | $-0.99 | ||
| Q3 24 | $0.02 | $-1.17 | ||
| Q2 24 | $-0.06 | $-1.05 | ||
| Q1 24 | $0.01 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | $161.6M | — |
| 股东权益账面价值 | $467.4M | $102.7M |
| 总资产 | $719.1M | $453.0M |
| 负债/权益比越低杠杆越低 | 0.35× | — |
8季度趋势，按日历期对齐
现金及短期投资FPIRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
总债务FPIRGNX
| Q4 25 | $161.6M | — | ||
| Q3 25 | $170.4M | — | ||
| Q2 25 | $193.4M | — | ||
| Q1 25 | $202.6M | — | ||
| Q4 24 | $204.6M | — | ||
| Q3 24 | $394.0M | — | ||
| Q2 24 | $393.0M | — | ||
| Q1 24 | $383.0M | — |
股东权益FPIRGNX
| Q4 25 | $467.4M | $102.7M | ||
| Q3 25 | $457.3M | $161.5M | ||
| Q2 25 | $473.5M | $213.7M | ||
| Q1 25 | $492.2M | $274.2M | ||
| Q4 24 | $494.6M | $259.7M | ||
| Q3 24 | $519.4M | $301.4M | ||
| Q2 24 | $521.5M | $348.3M | ||
| Q1 24 | $526.7M | $390.7M |
总资产FPIRGNX
| Q4 25 | $719.1M | $453.0M | ||
| Q3 25 | $738.5M | $525.2M | ||
| Q2 25 | $776.7M | $581.0M | ||
| Q1 25 | $810.5M | $490.9M | ||
| Q4 24 | $869.6M | $466.0M | ||
| Q3 24 | $1.0B | $519.1M | ||
| Q2 24 | $1.0B | $569.4M | ||
| Q1 24 | $1.0B | $629.2M |
负债/权益比FPIRGNX
| Q4 25 | 0.35× | — | ||
| Q3 25 | 0.37× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.41× | — | ||
| Q4 24 | 0.41× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 0.73× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.4M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | 0.81× | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流FPIRGNX
| Q4 25 | $17.4M | $-52.3M | ||
| Q3 25 | $-2.0M | $-56.0M | ||
| Q2 25 | $-2.2M | $-49.3M | ||
| Q1 25 | $6.4M | $33.6M | ||
| Q4 24 | $16.1M | $-31.6M | ||
| Q3 24 | $-4.3M | $-40.5M | ||
| Q2 24 | $-6.1M | $-45.5M | ||
| Q1 24 | $11.9M | $-55.5M |
自由现金流FPIRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率FPIRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度FPIRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率FPIRGNX
| Q4 25 | 0.81× | — | ||
| Q3 25 | -4.04× | — | ||
| Q2 25 | -0.29× | — | ||
| Q1 25 | 3.12× | 5.53× | ||
| Q4 24 | 0.27× | — | ||
| Q3 24 | -2.39× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 8.66× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FPI
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
